University of South Florida

About: University of South Florida is a education organization based out in Tampa, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 34231 authors who have published 72644 publications receiving 2538044 citations. The organization is also known as: USF.

Derivation of some modern arc magmas by melting of young subducted lithosphere

Abstract: MOST volcanic rocks in modern island and continental arcs are probably derived from melting of the mantle wedge, induced by hydrous fluids released during dehydration reactions in the subducted lithosphere1. Arc tholeiitic and calc-alkaline basaltic magmas are produced by partial melting of the mantle, and then evolve by crystal fractionation (with or without assimilation and magma mixing) to more silicic magmas2—basalt, andesite, dacite and rhyolite suites. Although most arc magmas are generated by these petrogenetic processes, rocks with the geochemical characteristics of melts derived directly from the subducted lithosphere are present in some modern arcs where relatively young and hot lithosphere is being subducted. These andesites, dacites and sodic rhyolites (dacites seem to be the most common products) or their intrusive equivalents (tonalites and trondhjemites) are usually not associated with parental basaltic magmas3. Here we show that the trace-element geochemistry of these magmas (termed 'adakites') is consistent with a derivation by partial melting of the subducted slab, and in particular that subducting lithosphere younger than 25 Myr seems to be required for slab melting to occur.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Abstract: BackgroundIn a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. MethodsIn this multicenter, phase 2 trial, we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior therapy. Patients received a target dose of 2×106 anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Secondary end points included overall survival, safety, and biomarker assessments. ResultsAmong the 111 patients who were enrolled, axi-cel was successfully manufactured for 110 (99%) and administered to 101 (91%)....

Method Variance in Organizational Research Truth or Urban Legend

Abstract: It has become widely accepted that correlations between variables measured with the same method, usually self-report surveys, are inflated due to the action of common method variance (CMV), despite a number of sources that suggest the problem is overstated. The author argues that the popular position suggesting CMV automatically affects variables measured with the same method is a distortion and oversimplification of the true state of affairs, reaching the status of urban legend. Empirical evidence is discussed casting doubt that the method itself produces systematic variance in observations that inflates correlations to any significant degree. It is suggested that the term common method variance be abandoned in favor of a focus on measurement bias that is the product of the interplay of constructs and methods by which they are assessed. A complex approach to dealing with potential biases involves their identification and control to rule them out as explanations for observed relationships using a variety ...

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Abstract: A b s t r ac t Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma. Methods We administered lambrolizumab intravenously at a dose of 10 mg per kilogram of body weight every 2 or 3 weeks or 2 mg per kilogram every 3 weeks in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not. Tumor responses were assessed every 12 weeks. Results A total of 135 patients with advanced melanoma were treated. Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade. The confirmed response rate across all dose cohorts, evaluated by central radiologic review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate observed in the cohort that received 10 mg per kilogram every 2 weeks (52%; 95% CI, 38 to 66). The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], respectively). Responses were durable in the majority of patients (median follow-up, 11 months among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of analysis in March 2013. The overall median progression-free survival among the 135 patients was longer than 7 months. Conclusions In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.)